Anti-angiogenesis effect of Baiying Juhua Decoction on the non-small cell lung cancer: integrating pharmacology, multi-machine learning and experimental investigation

Abstract

Baiying Juhua Decoction (BYJHD) is a well-established traditional Chinese herbal formula primarily composed of Solanum lyratum and chrysanthemum, which necessitates a thorough investigation to clarify its mechanisms in combating non-small cell lung cancer (NSCLC). This study employed a combination of network pharmacology predictions, serum pharmacochemistry analysis, and various machine learning algorithms (including LASSO, SVM-RFE, and RF) to identify 38 bioactive compounds that target 653 proteins associated with NSCLC. A cross-analysis of 2161 differentially expressed genes (DEGs) and 3124 functional modules led to the identification of 54 critical therapeutic targets. Following this, protein-protein interaction (PPI) and machine learning analysis pinpointed five key signaling regulators. Molecular docking studies demonstrated strong binding affinities between four representative compounds from BYJHD and these targets. Both in vitro and in vivo experiments confirmed that BYJHD inhibits the progression of NSCLC by exerting anti-angiogenic effects, specifically through the inhibition of the ACVRL-1/Smad/ID-1 signaling pathway and the downregulation of CD34. These findings effectively connect traditional clinical applications with contemporary mechanistic insights, positioning BYJHD as a promising multi-target therapeutic candidate for NSCLC.

Keywords

Non-small cell lung cancer / Network pharmacology / Serum medicinal chemistry / Machine learning / Baiying Juhua Decoction

References

[1] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, et al.. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263

[2] Cunha SI, Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood, 2011, 117(26): 6999-7006

[3] Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkels L, et al.. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med, 2010, 207(1): 85-100

[4] Cunha SI, Bocci M, Lövrot J, Eleftheriou N, Roswall P, et al.. Endothelial ALK1 is a therapeutic target to block metastatic dissemination of breast cancer. Cancer Res, 2015, 75(12): 2445-2456

[5] Fan Y, Ma Z, Zhao L, Wang W, Gao M, et al.. Anti-tumor activities and mechanisms of traditional Chinese medicines formulas: a review. Biomed Pharmacother, 2020, 132: 110820

[6] Fan J, Xia X, Fan Z. Hsa_circ_0129047 regulates the miR-375/ACVRL1 axis to attenuate the progression of lung adenocarcinoma. J Clin Lab Anal, 2022, 36(9): e24591

[7] Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, et al.. A phase I study of the anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962 in patients with advanced solid tumors. Clin Cancer Res, 2016, 22(92146-2154

[8] Greene JA, Loscalzo J. Putting the patient back together - social medicine, network medicine, and the limits of reductionism. N Engl J Med, 2017, 377(252493-2499

[9] Hao H, Guo Z, Li Z, Li J, Jiang S, et al.. Modified Bu-Fei Decoction inhibits lung metastasis via suppressing angiopoietin-like 4. Phytomedicine, 2022, 106: 154409

[10] Harada G, Yang SR, Cocco E, Drilon A. Rare molecular subtypes of lung cancer. Nat Rev Clin Oncol, 2023, 20(4): 229-249

[11] Hawinkels LJ, Garcia de Vinuesa A, Ten Dijke P. Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy. Expert Opin Investig Drugs, 2013, 22(111371-1383

[12] Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, et al.. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res, 2011, 71(4): 1362-1373

[13] Ji P, Xu J, Li M, Song C, Zhang Y, et al.. A novel paradigm defines functional molecule clusters for an anti-Alzheimer’s disease recipe from traditional Chinese medicine. Am J Chin Med, 2023, 51(7): 1823-1843

[14] Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, et al.. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer, 2016, 122(23): 3641-3649

[15] Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, et al.. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer, 2023, 22(1): 40

[16] Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol, 2023, 20(9624-639

[17] Li Z, Feiyue Z, Gaofeng L. Traditional Chinese medicine and lung cancer–from theory to practice. Biomed Pharmacother, 2021, 137: 111381

[18] Liao XZ, Gao Y, Sun LL, Liu JH, Chen HR, et al.. Rosmarinic acid reverses non-small cell lung cancer cisplatin resistance by activating the MAPK signaling pathway. Phytother Res, 2020, 34(5): 1142-1153

[19] Lu T, Yu J, Gao R, Wang J, Wang H et al (2023) Chinese patent medicine Kanglaite injection for non-small-cell lung cancer: an overview of systematic reviews. J Ethnopharmacol. ;302(Pt A):115814.

[20] Meyer mL, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Jänne PA, et al.. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet, 2024, 404(10454803-822

[21] Moon JY, Manh Hung LV, Unno T, Cho SK (2018) Nobiletin enhances chemosensitivity to adriamycin through modulation of the Akt/GSK3β/β⁻Catenin/MYCN/MRP1 signaling pathway in A549 human Non-Small-Cell lung cancer cells. Nutrients 10(12)

[22] Nawaz K, Webster RM. The non-small-cell lung cancer drug market. Nat Rev Drug Discov, 2023, 22(4): 264-265

[23] Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, et al.. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci, 2022, 43(2): 136-150

[24] Noor F, Asif M, Ashfaq UA, Qasim M, Tahir Ul Qamar M (2023) Machine learning for synergistic network pharmacology: a comprehensive overview. Brief Bioinform 24(3)

[25] Peng H, Huang Z, Li P, Sun Z, Hou X, et al.. Investigating the efficacy and mechanisms of Jinfu’an Decoction in treating non-small cell lung cancer using network pharmacology and in vitro and in vivo experiments. J Ethnopharmacol, 2024, 321: 117518

[26] Pintha K, Chaiwangyen W, Yodkeeree S, Suttajit M, Tantipaiboonwong P (2021) Suppressive effects of rosmarinic acid rich fraction from perilla on oxidative stress, inflammation and metastasis ability in A549 cells exposed to PM via C-Jun, P-65-Nf-Κb and Akt signaling pathways. Biomolecules 11(8)

[27] Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, et al.. Non-Small cell lung Cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2024, 22(4): 249-274

[28] Schoonderwoerd MJA, Goumans MTH, Hawinkels L (2020) Endoglin: beyond the endothelium. Biomolecules 10(2)

[29] Schulze AB, Schmidt LH, Heitkötter B, Huss S, Mohr M, et al.. Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLC. Thorac Cancer, 2020, 11(1120-129

[30] Simonelli M, Zucali P, Santoro A, Thomas MB, de Braud FG, et al.. Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. Ann Oncol, 2016, 27(9): 1782-1787

[31] Sp N, Kang DY, Lee JM, Jang KJ (2021) Mechanistic insights of antiiImmune evasion by nobiletin through regulating miR-197/STAT3/PD-L1 signaling in Non-Small cell lung cancer (NSCLC) cells. Int J Mol Sci 22(18)

[32] Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, et al.. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res, 2001, 7(11): 3410-3415

[33] Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, et al.. Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: comparison between CD105 and CD34 as a marker of angiogenesis. Lung Cancer (Amsterdam Netherlands), 2003, 39(3): 289-296

[34] Tian D, Chen W, Xu D, Xu L, Xu G, et al.. A review of traditional Chinese medicine diagnosis using machine learning: inspection, auscultation-olfaction, inquiry, and palpation. Comput Biol Med, 2024, 170: 108074

[35] Wang ZY, Wang X, Zhang DY, Hu YJ, Li S. Traditional Chinese medicine network pharmacology: development in new era under guidance of network pharmacology evaluation method guidance. Zhongguo Zhong Yao Za Zhi, 2022, 47(1): 7-17

[36] Wang C, Yuan X, Xue J. Targeted therapy for rare lung cancers: status, challenges, and prospects. Mol Ther, 2023, 31(71960-1978

[37] Wei Z, Chen J, Zuo F, Guo J, Sun X, et al.. Traditional Chinese medicine has great potential as candidate drugs for lung cancer: a review. J Ethnopharmacol, 2023, 300: 115748

[38] Xiong F, Jiang M, Huang Z, Chen M, Chen K, et al.. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells. Integr Cancer Ther, 2014, 13(2152-160

[39] Xu L, Ru X, Song R. Application of machine learning for drug-target interaction prediction. Front Genet, 2021, 12: 680117

[40] Zhang P, Zhang D, Zhou W, Wang L, Wang B et al (2023) Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine. Brief Bioinform 25(1)

[41] Zhou H, Chen Y, Jiang N, Ren Y, Zhuang J et al (2024) Epoxymicheliolide reduces Radiation-Induced senescence and extracellular matrix formation by disrupting NF-κB and TGF-β/SMAD pathways in lung cancer. Phytother Res

[42] Zhu C, Cai T, Jin Y, Chen J, Liu G, et al.. Artificial intelligence and network pharmacology based investigation of pharmacological mechanism and substance basis of Xiaokewan in treating diabetes. Pharmacol Res, 2020, 159: 104935

Funding

Shandong Province Traditional Chinese Medicine Project(Q2022-012)

RIGHTS & PERMISSIONS

The Author(s)